

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**VOLUNTARY ANNOUNCEMENT
STRATEGIC CO-OPERATION FRAMEWORK AGREEMENT**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that on 9 November 2021 (after trading hours), the Company entered into a strategic co-operation framework agreement (the “**Framework Agreement**”) with Tianda Pharmaceuticals Limited (SEHK stock code: 0455.HK) (“**Tianda Pharmaceuticals**”) to commence strategic co-operation for a period of three years in the following areas:

1. Both parties will jointly evaluate and invest in projects in medical technology and medical services with potentials, including equity investments in other listed and unlisted companies;
2. The modern Chinese medical clinic chain “TDMall” and health management centers operated by Tianda Pharmaceuticals will (i) recommend the Company’s longevity medical services to its members (“**TDMall Members**”), and (ii) provide quality Chinese medicine services to the members of the Company; and
3. The Company, with its operations in longevity medical examination services and providing scientific solutions for health and longevity, will (i) recommend the Chinese medicine services by Tianda Pharmaceuticals to its members, and (ii) provide quality longevity medical services to the TDMall Members.

Information on Tianda Pharmaceuticals

Tianda Pharmaceuticals (SEHK stock code: 0455.HK) implements the strategies of development of Traditional Chinese Medicine as its foundation, development of innovative drugs and medical technologies, as well as development of high-quality medical and healthcare services. Tianda Pharmaceuticals is committed to become a leading pharmaceutical enterprise setting its footholds in China with business presence globally.

Reasons for and Benefits of Entering into the Framework Agreement

The Board believes that the Framework Agreement can further improve the Group's global presence in the field of longevity science, further enhance the Group's leading position in the longevity medical industry chain and bring stable and sustainable growth in revenue to the Group in the long run.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman

Hong Kong, 9 November 2021

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Wang Hongxin (*Chief Executive Officer*)
Mr. Li Xiaoshuang
Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Tam Ho Leung Simon
Ms. Wang Weixia
Mr. Chai Nan

Non-executive Directors

Dr. He Yiwu
Ms. Choi Ngai Wah

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.